Garces Kirsten
Issues Emerg Health Technol. 2003 Nov(52):1-4.
Insulin glargine is a once-daily, biosynthetic, human insulin analogue. Some trials show that in patients with type 1 diabetes mellitus, insulin glargine offers an advantage in blood glucose control compared with NPH insulin. There is some evidence of decreased nocturnal and symptomatic hypoglycemia in patients receiving insulin glargine compared with those receiving NPH insulin, but there are no significant differences in the incidence of severe hypoglycemia. Insulin glargine is approved for use in Canada, but it has not yet been marketed.
甘精胰岛素是一种每日注射一次的生物合成人胰岛素类似物。一些试验表明,在1型糖尿病患者中,与中性鱼精蛋白锌胰岛素相比,甘精胰岛素在血糖控制方面具有优势。有证据表明,与接受中性鱼精蛋白锌胰岛素的患者相比,接受甘精胰岛素的患者夜间及有症状低血糖的发生率有所降低,但严重低血糖的发生率无显著差异。甘精胰岛素在加拿大已获批使用,但尚未上市。